Cancers caused by human papillomavirus (HPV) are a significant public health problem in the United States. But these cancers are preventable with HPV vaccination.
Drug simultaneously protects healthy tissue from harmful radiation side-effects.
University of Iowa Holden Comprehensive Cancer Center has received its fourth renewal as a comprehensive cancer center from the National Cancer Institute (NCI), part of the National Institutes of Health.
Benjamin J. Miller, MD, MS, discusses the creation of the Musculoskeletal Tumor Registry and how it is poised to make progress in the orthopedic oncology field with OncLive.
Work led by team at University of Iowa Holden Comprehensive Cancer Center enables greater access to targeted diagnosis and treatment of rare cancer
People with a rare cancer will have greater access to a drug enabling targeted diagnosis and treatment, thanks to work led by a team of researchers at University of Iowa Health Care’s PET Imaging Center.
Holden oncologist Muhammad Furqan, MD, receives NCI award for dedication to lung cancer clinical research
Furqan is one of eight recipients nationwide of the Cancer Clinical Investigator Team Leadership Award for outstanding work leading clinical trials.
Sarcoma patients treated at high-volume medical centers may have higher survival rates than those treated at low-volume centers.
Cancer researchers at two Iowa universities are collaborating on research to address cancer similarities in humans and their companion animals.
The study’s findings may provide insight on new approaches or combination therapies to improve other forms of chemotherapy and limit side effects.
The European Neuroendocrine Tumor Center of Excellence designation demonstrates Holden’s full commitment to neuroendocrine tumor care and prevention.